Affordable Access

Publisher Website

Plasma concentrations of 9-deoxo-16,16-dimethyl-9-methylene-PGE2in Rhesus monkeys after administration by various routes

Authors
Journal
Prostaglandins & Other Lipid Mediators
0090-6980
Publisher
Elsevier
Publication Date
Volume
20
Issue
3
Identifiers
DOI: 10.1016/0090-6980(80)90043-x

Abstract

Abstract A method is described for the estimation of 9-deoxo-16,16-dimethyl-9-methylene-PGE 2 by double antibody radioimmunoassay. Plasma samples obtained from animals treated with 9-methylene-16,16-dimethyl-PGE 2,1-adamantanamine salt were extracted with diethyl ether to recover the prostaglandin. The validation of sample preparation and assay procedure are presented. Rhesus females were treated by several routes of administration and the samples assayed for drug content. Maximum blood levels were probably reached 30 minutes following subcutaneous injection and within 30 seconds of an intravenous injection. Results of the acute intravenous injection indicate an initial half-life of approximately one minute in peripheral circulation. Continuous intravenous infusion at 3 increasing doses of this compound resulted in a stepwise increase in plasma drug concentrations. Vaginal administration of 9-methylene-16,16-dimethyl-PGE 2,1-adamantanamine salt in suppositories produced a dose dependent increase in plasma drug concentration. Higher plasma drug concentrations were produced when the prostaglandin was delivered in H-15 base suppositories than in E-76 base suppositories.

There are no comments yet on this publication. Be the first to share your thoughts.